Instead of targeting GLP-1 and GIP, survodutide targets GLP-1 and glucagon receptors
Conclusion When comparing L-citrulline and L-arginine, the key differences lie in their bioavailability, duration of effects, and specific health applications
After treatment, there were significant improvements in insulin sensitivity, testosterone levels, and markers of inflammation
The same consensus moved overweight to BMI 23 and obese to BMI 25 for Asian Indians
2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) (63)